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INTRODUCTION 
The p63 gene is a member of the p53 gene family and it
shares a high degree of homology and remarkable structural
similarity with p53 gene (1, 2). Therefore, the p63 protein
was originally thought to be another tumor suppressor func-
tioning in a similar capacity to p53. However, p63 has been
demonstrated to have divergent roles. It is a key transcrip-
tional regulator of the proliferation and differentiation cas-
cade in stratified epithelia (3), it exhibits tissue-specific roles
in normal development and a complex contribution to tumori-
genesis which is due to its expression as multiple protein iso-
forms (4). According to different amino terminals, p63 has
two major isoforms: TAp63 and  Np63. TAp63 has a trans-
activating amino terminal while  Np63 has a dominant
negative activating amino terminal (5-8). In general, the
TAp63 isoform behaves like p53 because they transactivate
various p53 downstream targets and induce apoptosis, medi-
ate cell cycle control. In contrast, the  Np63 isoform has
been shown to display functions opposite to that of the TAp63
isoform, including acting as oncoproteins (9-12).  Np63
overexpression is often observed in and enhances oncogenic
growth of squamous cell carcinomas (11, 13).  Np63 could
function as dominant-negative molecule against the p53 tumor
suppressor activities (5).  Np63 overexpression induces nucle-
ar accumulation of β -catenin and activates β -catenin signal-
ing that promotes cell proliferation (12). Nowadays, many
researchers tend to agree with the concept that TAp63 plays
a more p53-like role, whereas  Np63 has an antagonistic
or even oncogenic role in cancer progression (11, 14-17).
Our previous study demonstrated that  Np63 was over-
expressed in human transitional cell carcinoma of bladder
(TCCB) tissues at both mRNA and protein levels, so we
hypothesize that  Np63 promotes the survival and prolifera-
tion of both epithelial stem cells and TCCB cells. However,
the specific role of  Np63 in TCCB development remains
largely unclear and the mechanisms by which  Np63 pro-
motes cell survival remain to be elucidated. Understanding
the regulation and mechanistic contributions of  Np63 in
TCCB may ultimately provide new therapeutic opportuni-
ties for this disease. Thus, the objective of this study was to
better understand the functions of  Np63 in TCCB with a
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Impaired Delta Np63 Expression is Associated with Poor Tumor
Development in Transitional Cell Carcinoma of the Bladder
The oncogenic isoform of the p63 protein, delta Np63 ( Np63), plays an important
role in the pathogenesis of many epithelial carcinomas, and emerging evidences
suggest that  Np63 is a promising drug target. However, the functions of  Np63
in transitional cell carcinoma of bladder (TCCB) are poorly defined. In this study, a
Np63 shRNA expression vector was transfected into TCCB cell line 5637 and
cell cycling, cell proliferation and protein expression were assessed by flow cytom-
etry and 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-dimethyl tetrazolium bromide (MTT) assay,
and immunohistochemistry, respectively. The  Np63 shRNA expression vector
was also injected into 5637 cell xenograft tumors in nude mice, and tumor size was
measured, tumor tissue morphology was assessed by immunohistopathology and
transmission electron microscopy. In the in vitro study,  Np63 shRNA transfection
caused successful  Np63 gene silencing and resulted in significant arrest of cell
cycling and cellular proliferation (p<0.05) as well as cyclin D1 expression. In the
nude mouse xenograft model,  Np63 shRNA greatly inhibited tumor growth, induc-
ed tumor cell apoptosis (p<0.05) and resulted in cyclin D1 downregulation. Our
data suggest that  Np63 may play an oncogenic role in TCCB progression through
promoting cell survival and proliferation. Intratumoral administration of  Np63-spe-
cific shRNA suppressed tumor  Np63 expression and cellular proliferation while
promoted tumor cellular apoptosis, and therefore inhibited tumor growth and improv-
ed survival of xenograft-bearing mice, which was not accompanied by significant
signs of systemic toxicity. 
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Accepted : 1 February 2008human TCCB cell line 5637 in vitro and in a nude mouse
xenograft model where the expression of  Np63 was silenced
by RNA interference (RNAi) technology.
MATERIALS AND METHODS
Plasmid construction 
A pair of effective short hairpin RNA (shRNA) against
Np63 mRNA was selected from a preliminary experiment.
The pair of shRNA forms a structure consisting of two 19-
bp stem targeting  Np63 mRNA, a 9-bp loop and a short
poly(A)6 sequence. Two oligonucleotides, forward, 5′ -GAT-
CCGTGCCCAGACTCAATTTAGTTTCAAGACGACT-
AAATTGAGTCTGGGCATTTTTTGTCGACA-3′ , reverse,
5′ -AGCTTGTCGACAAAAAATGCCCAGACTCAATT-
TAGTCGTCTTGAAACTAAATTGAGTCTGGGCACG-
3′ , were synthesized and ligated directly into BamHI and
HindIII linearized genesil-1 plasmid (Jingsai Inc, Wuhan,
China). The recombinant  Np63-shRNA expression con-
struct, p Np63-shRNA, was confirmed by using PstI+SalI
double digestion and by gene sequencing. The negative con-
trol plasmid, termed p Np63-cRNA has an sequence insert
at the same place from the following two oligonucleotides:
forward, 5′ -GATCCGACTTCATAAGGCGCATGCTTC-
AAGACGGCATGCGCCTTATGAAGTCTTTTTTGT-
CGACA-3′ ; reverse, 5′ -AGCTTGTCGACAAAAAAGAC-
TTCATAAGGCGCATGCCGTCTTGAAGCATGCGC-
CTTATAAGTCG-3′ . 
Cell culture and transfection 
Human TCCB cell line 5637 was purchased from the
Institute of Cell Research, Shanghai, Chinese Academy of
Sciences. The cells were cultured in RPMI 1640 medium
(Gibico, Shanghai, China) supplemented with 10% fetal
bovine serum (FBS, Sijixin Inc., Beijing, China) and 1%
penicillin-streptomycin (Invitrogen, Shanghai, China). All
cells were cultured at 37℃ with 5% CO2. For transfection,
cells were seeded in 6-well plates at 1×106 cells per well
and allowed to grow overnight to approximately 80% con-
fluence. For each well, cells were transfected with the mix-
ture of 0.4 μ g p Np63-shRNA or p Np63-cRNA or 0.4
μ L phosphate-buffered solution (PBS) and 10 μ L Effectene
transfection reagent (Qiagen, Shanghai, China) in 600 μ L
fresh 1640 culture medium. Forty-eight hours after trans-
fection, cells were harvested for immunocytochemistry, reverse
transcription polymerase chain reaction (RT-PCR) or flow
cytometry analysis as described below. 
Immunocytochemistry 
Cells were fixed with pre-chilled acetone at 4℃for 30 min,
then incubated for 10 min with 3% hydrogen peroxide in
methanol. Goat non-immune serum was used to block the
non-specific binding. Cells were incubated overnight at 4℃
with a 1:200 dilution of mouse monoclonal anti- Np63
antibody (Santa Cruz, Shanghai, China) or with a 1:100
dilution of rabbit anti-cyclin D1 polyclonal antibody (Santa
Cruz). Then cells were washed three times and an appropriate
biotinylated-conjugated secondary antibody (Santa Cruz)
with a 1:150 dilution was applied for 15 min at 37℃. Cells
were washed three times and then incubated with strepta-
vidin peroxidase (SP, Zhongshan Golden Bridge Inc., Bei-
jing, China) for 15 min at 37℃. Then horseradish peroxi-
dase substrate diaminobenzidine solution was then added
for 15 sec and the staining was stopped by washing the cover-
slip with water repeatedly. Finally, cells were counterstained
with hematoxylin. 
Semiquantitative multiplex RT-PCR 
Total RNA was extracted from tissue homogenates or cell
lysates with TRIzol reagent (Invitrogen) and RT-PCR was
carried out with a RNA PCR Kit Ver.3.0 (TaKaRa, Dalian,
China) according to the kit’s instructions. The primers used
for  Np63 were: forward, 5′ -TGCCCAGACTCAATTTA-
GTGAG-3′ ; reverse, 5′ -TCTGGATGGGGCATGTCTT-
TGC-3′ , which yields a product of 335 bp. The primers
used for β -actin were: forward, 5′ -GTGGACATCCGCAA-
AGAC-3′ ; reverse, 5′ -AAAGGGTGTAACGCAATCAA-
3′ , which yields a product of 302 bp. The PCR condition
was: 94℃for 2 min, then 35 cycles at 95℃for 1 min, 53℃
for 0.5 min, and 72℃ for 1 min in 1.5 mM MgCl2-contain-
ing reaction buffer. Five microliters of RT-PCR products
were resolved on 1.5% agarose gels. The gels were stained
with ethidium bromide (EB) and were scanned for densito-
metric estimation of the  Np63 products with β -actin prod-
ucts serving as the internal control.
Cell cycle assay with flow cytometry 
A total of 1×106 cells treated with p Np63-shRNA vec-
tor or p Np63-cRNA vector were trypsinized and washed
with PBS twice. Then cells were transferred and fixed in pre-
chilled 75% ethanol at 4℃ overnight. After three times of
wash, cells were digested with 1% RNase at 37℃for 30 min
and stained with 50 μ g/mL propidium iodide (PI, Sigma,
Shanghai, China) for 1 hr at 4℃. Samples were assayed by a
Coulter Epics XL flow cytometer (Beckman-Coulter Inc.,
NewYork, NY, U.S.A.) and data were analyzed with Multi-
cycle DNA content and cell analysis software.
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-dimethyl tetrazolium
bromide (MTT) assay for cell proliferation 
Cells in logarithmic growth phase were seeded in 96-well
826 Y. He, X. Wu, W. Tang, et al.plates at 2×104 cells per well. Then cells were transfected
with p Np63-shRNA or p Np63-cRNA or PBS and con-
tinued to culture for 24, 48, 72, 96, and 120 hr respective-
ly. Four hours before stop culturing, 20 μ L of 5 mg/mL MTT
(Sigma) was added to the culture medium. After incubation,
the culture medium was removed and 200 μ L of dimethyl-
sulphoxide (DMSO) was added to resolve the crystal. Absor-
bance was measured at 490 nm. Each sample was assayed
for four times. 
Nude mouse xenograft model 
Female BALB/c nude mice, 4 weeks of age, weighting 13
±0.5 g, were purchased from Experimental Animal Center
of Chinese Academy of Sciences, Shanghai, China. Mice were
housed in microisolator cages in a specific pathogen-free (SPF)
condition with 12-hr light-dark cycles. Mice were subcuta-
neously implanted with 2×106 5637 cells. Once tumors
reached approximately 60 μ L in volume, the mice were allo-
cated to receive either p Np63-shRNA or p Np63-cRNA
vector or PBS. Complexes of 20 μ g vector (or PBS)+4 μ L in
vivo-jetPEITM (polyplus-transfection Inc., Shanghai, China)+
160 μ L 5% glucose were directly injected into the tumor
once a week for five weeks. Tumor dimensions were measured
weekly and the tumor volumes calculated using the formu-
la: [1/2]×a×b2, where a and b, respectively, represented the
larger and smaller tumor diameter. At the end of the five
week treatment, mice were killed by overdose of ketamine
(400 mg/kg) and xylazine (50 mg/kg) and necropsy was
performed. Tumor tissue samples were prepared for immuno-
histochemistry or RT-PCR or transmission electron micro-
scopy. Tumor growth inhibition (TGI) was calculated using
the formula TGI (%)=(1-MT/MC)×100, where MT and MC
are the mean tumor masses in the treatment group, and con-
trol group, respectively. 
Morphologic and immunohistochemical assessment of
apoptosis in nude mouse xenograft model 
For histological examination, tumor tissue samples were
fixed with 4% paraformaldehyde for 72 hr, dehydrated in grad-
ed ethanol, and embedded in paraffin. Samples were cut into
5-μ m-thick sections and stained by hematoxylin-eosin (HE).
For transmission electron microscopy, tumor tissue sam-
ples were cut into sections approximately 1×1 mm, fixed
with 4% paraformaldehyde for 2 hr, and then transferred
into pre-chilled 1% glutaraldehyde. The samples were dehy-
drated in graded ethanol, embedded in epon 812, and then
cut into ultrathin or semithin sections. The sections were
stained and examined under a Hitachi-800 transmission elec-
tron microscope. 
For tumor tissue immunohistochemistry, sections of 5-μ m-
thick paraffin-embedded tissue microarrays were deparaffiniz-
ed and rehydrated with xylene and ethanol. The immunos-
taining procedures were the same with the immunocytochem-
istry described above.
Statistical analysis 
The results were expressed as mean±deviation. One-way
analysis of variance (ANOVA) was used to determine the
levels of difference between all groups. Comparisons for all
pairs were made using Student-Newman-Keuls (SNK) test.
p<0.05 was considered statistically significant. 
RESULTS 
Np63 mRNA and protein expression were inhibited by
Np63 shRNA in vitro and in vivo
As previously reported (18), TCCB cell line 5637 inher-
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Fig. 1. The mRNA expression of  Np63 in 5637 cells 48 hr post-transfection, assayed by semiquantitative RT-PCR. (A) Products were
analyzed on a 1.5% agarose gel. The 335 bp band is  Np63 mRNA. The 302 bp band is β -actin serving as the internal control. (B) Quantified
expression levels of  Np63 as normalized to the β -actin level. *Statistically significant (p<0.05, mean±SD, n=10) relative to control shRNA.
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Expression levels of  Np63 mRNAently expresses high levels of  Np63. Following transfec-
tion of p Np63-shRNA, at 48 hr later, the relative  Np63
mRNA expression levels ( Np63/β -actin) were 0.156±0.07
for cells transfected with p Np63-shRNA, 0.749±0.02 for
cells transfected with the control vector, and 0.786±0.04
for cells transfected with PBS. Compared with the control
RNA vector, the expression levels of  Np63 mRNA were sig-
nificantly inhibited by  Np63 shRNA (p<0.05) (Fig. 1). 
The expression levels of  Np63 protein were detected at
48 hr post-transfection by immunocytochemistry.  Np63
proteins positive cells should be stained brown in the nuclei.
Cells transfected with PBS or the control vector were strong-
ly stained in the nuclei (Fig. 2A, B), while cells transfected
with p Np63-shRNA were only weakly stained in the nuclei
(Fig. 2C). These demonstrated that  Np63 shRNA inhib-
ited  Np63 protein expression significantly.
Similar suppressions of  Np63 mRNA and protein expres-
sion by  Np63 shRNA were found in the nude mouse xeno-
graft model by semiquantitative RT-PCR and immunohis-
tochemistry.
Np63 shRNA caused cell cycle arrest of 5637 cells in
vitro 
Cell cycling of 5637 cells was assessed by flow cytometry.
The percentage of cells in G0/G1 phase for cells transfected
with p Np63-shRNA, p Np63-cRNA or PBS was respec-
tively 66.38±3.08%, 52.58±2.03% and 48.27±0.84%.
The percentage of cells in S phase for the three groups was
33.68±2.06%, 39.82±1.89% and 40.50±0.58%, respec-
tively (Fig. 3). These results indicated that a significant per-
centage of 5637 cells were arrested in G0/G1 phase after treat-
ment of  Np63 shRNA. 
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Fig. 2. Expression of  Np63 protein in TCCB 5637 cell line was assayed by immunocytochemistry at 48 hr post-transfection with the indi-
cated vector or medium (original magnification, ×200).
A B C
PBS p   Np63-cRNA p   Np63-shRNA
Fig. 3. Cell cycle progression of 5637 cells following different treat-
ments as indicated. (A) Flow cytometry graphs. (B) Quantification
of the percentages of cells in G0/G1 phase and S phase. 
*Statistically significant (p<0.05, mean±SD, n=10) relative to con-
trol shRNA.
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HourNp63 shRNA inhibited 5637 cell proliferation in vitro
Proliferation of 5637 cells was evaluated with the MTT
assay (Fig. 4). The absorbance-time curves showed that the
absorbance of cells transfected with p Np63-shRNA was
significantly lower than that of cells treated with the con-
trol vector or PBS. The difference is especially significant at
120 hr post-transfection. The result indicated that the pro-
liferation of TCCB cell line 5637 was significantly inhibited
by Np63 gene  silencing. 
Np63 expression suppression led to down-regulation
of cyclin D1 in vitro and in vivo
The effects of  Np63 gene silencing on the expression of
cyclin D1 was evaluated by immunochemistry staining which
was performed both in 5637 cell line in vitro and in nude
mouse xenograft tumor. Cells with positive cyclin D1 pro-
tein expression should be stained brown in the nuclei. Both
in 5637 cells in culture (Fig. 5) and in its nude mouse xeno-
graft tumor (Fig. 6), cells transfected with p Np63-shRNA
were stained weakly positive in the nuclei, while cells treat-
ed with PBS or the control vector were stained strongly posi-
tive in the nuclei. These results suggested that silencing of
Np63 expression is associated with downregulation of
cyclin D1 expression in 5637 cells. 
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Fig. 5. Cyclin D1 protein expression in TCCB 5637 cell line at 48 hr post-transfection of  Np63 specific or control shRNA or PBS. Assayed
by immunocytochemistry (original magnification, ×200). 
A B C
PBS p   Np63-cRNA p   Np63-shRNA
Fig. 6. Cyclin D1 protein expression in TCCB 5637 xenograft tumors from nude mice treated with PBS,  control shRNA vector or  Np63 specific
shRNA vector. Tumor tissues were taken at the end of the experiment and assayed by immunocytochemistry (original magnification,×200). 
A B C
PBS p   Np63-cRNA p   Np63-shRNA
Fig. 7. Tumors were taken at 8 weeks from treatment from mice
treated with p Np63-shRNA (A1), p Np63-cRNA (A2) or PBS
(A3) and their sizes were measured and shown in B.
*Statistically significant (p<0.05, mean±SD, n=6) relative to p
Np63-cRNA group.
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in vivo 
Tumor volumes were determined weekly. At the end of
the experiment, mice receiving p Np63-shRNA exhibited
a 74.44% reduction in final tumor size relative to mice treated
with p Np63-cRNA and tumor-bearing mice treated with
PBS had a similar tumor size as the control shRNA group
(Fig. 7). Neither group exhibited signs of systemic toxicity
or metastasis. 
Morphologic changes in tumor
Histological assessment revealed that, compared to con-
trol shRNA and PBS treated mice, more inflammatory cells
and sometimes zones of necrosis were found in tumor tis-
sues of mice treated with p Np63-shRNA (data not shown).
Transmission electron microscopy indicated that disintegra-
tion of nucleolus, vacuoles in cytoplasm, inflammatory cell
infiltration and apoptotic body formation could be observed
in tumor tissues treated with P Np63-shRNA (Fig. 8A,
B) which were rarely seen in tumor tissues treated with the
P Np63-cRNA or PBS (Fig. 8C, D) 
DISCUSSION
The ability of RNAi mediated by shRNA to silence indi-
vidual gene expression with a high degree of specificity pre-
sents a unique opportunity to study gene functions (19, 20).
Plasmid and viral vectors producing shRNA using the poly-
merase III promoter offer efficient and stable gene silencing
(21, 22). In this study, we constructed a  Np63 shRNA
expression plasmid, which achieved efficient and specific 
Np63 gene silencing in human TCCB cell line 5637 follow-
ing transfection both in vitro and in a nude mouse xenograft
model. With  Np63 gene silencing, the cell cycle of 5637
cells was arrested in G0/G1 phase and cellular proliferation
was significantly suppressed.  Np63 gene silencing by spe-
cific shRNA in the nude mouse xenograft tumor resulted in
marked retardation of tumor growth and increase in tumor
cell apoptosis. Our data suggested that  Np63 might play
an oncogenic role in TCCB progression through promoting
cell survival and proliferation. Therefore,  Np63 might be
a new target gene for TCCB gene therapy, and  Np63
shRNA might be a novel and promising approach for silenc-
ing Np63  expression.
One interesting new finding in our study is that cyclin
D1 expression was downregulated after silencing of  Np63
expression in 5637 cells both in vitro and in vivo, indicat-
ing cyclin D1 might be a target gene of  Np63.  Np63
shares homology with the DNA-binding domain of p53,
and numerous studies have reported that  Np63 proteins
could bind to p53 consensus DNA sequences (23, 24). Cyclin
D1 had previously been identified to have a p53 binding
site. Cyclin D1 is a key regulator of cell cycle progression
and a proven oncogene in several cancers, including urinary
bladder carcinoma (25). It regulates cell cycle progression
by activating cyclin-dependent kinases 4 and 6 (CDK4 and
CDK6), which in turn phosphorylates the retinoblastoma
protein (Rb), leading to the inactivated pRB, releasing of
transcription factor E2F and cell progression through G1/S
checkpoint (26-30). The strong positive correlation between
Np63 and cyclin D1 expression found in our study sug-
gests that  Np63 might regulate TCCB cell cycle through
regulating the expression of cyclin D1 which leads to less
efficient phosphorylation of Rb which is a key condition for
cells to pass G1/S regulation point (31, 32). Therefore, cyclin
D1 downregulation could lead to cell cycle arrest in G0/G1
phase, inhibition of cellular proliferation and promotion of
apoptosis. 
In conclusion, this study demonstrated that  Np63 plays
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Fig. 8. Transmission electron microscopic examination of TCCB xenograft tumor tissues. Tumor tissues were from mice treated with p
Np63-shRNA (A, B), p Np63-cRNA A (C) or PBS (D). (A) Tumor tissues treated with p Np63-shRNA; the arrows indicate the apoptotic
cells. (B) Tumor tissues treated with pNp63-shRNA; the arrow indicate the inflammatory cells. (C) Tumor tissues treated with p Np63-
cRNA. (D) Tumor tissues treated with PBS.
A B C D 5 μ m 2 μ m 5 μ m 5 μ man oncogenic role in TCCB cells. Targeting this oncoprotein
using a shRNA expressing vector induced specific silencing
of the gene. Suppression of  Np63 expression impaired
TCCB tumor growth in vivo and improved the survival of
tumor-bearing nude mice. These effects are associated with
impaired cellular proliferation and increased apoptosis. At
the molecular level, our study suggests that cyclin D1 might
be one of the target genes of  Np63. 
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